Pédiatrie Neuroblastomes
NANT 2015-02 (IC 2018-05)
Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma
Paris
GUDRUN SCHLEIERMACHER